ClinicalTrials.gg
Not yet recruitingNCT07698561LINZA-RIFUpdated Oct 21, 2026

Linzagolix in Adenomyosis and Recurrent Implantation Failure

An observational study in Adenomyosis of Uterus, Implantation Failure and Infertility Female, sponsored by Vida Fertility Institute. Not yet recruiting at 3 sites in Spain. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Vida Fertility Institute · Observational

How we know

Updated Oct 21, 2026Start date movedEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

Adenomyosis is associated with impaired endometrial receptivity and reduced implantation rates in assisted reproduction, even when using high-quality embryos. Linzagolix (Yselty, 200 mg) is an oral GnRH receptor antagonist approved for uterine fibroids with a favourable tolerability profile and rapid elimination half-life (18-20 hours) compared to GnRH agonists.

This prospective case series evaluates the efficacy of linzagolix 200 mg administered for 3 to 6 months prior to embryo transfer in patients with confirmed adenomyosis and recurrent implantation failure (RIF), defined as ≥2 failed transfers with high-quality blastocysts (≥BB Gardner in oocyte donation, or PGT-A confirmed euploid in autologous cycles).

The primary endpoint is the live birth rate (LBR) per embryo transfer. Secondary endpoints include clinical pregnancy rate, miscarriage rate, morphological response of adenomyosis (uterine volume and junctional zone [JZ] thickness assessed by standardised transvaginal ultrasound), and tolerability profile. The study also explores the optimal treatment duration (3 vs 6 months) as a sub-analysis based on morphological response at the month-3 visit.

The study is conducted at three centres of Vida Fertility Institute (Madrid, Alicante and San Sebastián, Spain). Sample size: n=30 patients. Study duration: 24 months.

Read the detailed description

BACKGROUND:

Current standard of care for adenomyosis prior to embryo transfer in RIF patients consists of GnRH agonist therapy (triptorelin depot) for 1-3 months, with or without letrozole. This approach requires intramuscular administration, is associated with intense vasomotor symptoms, and has a prolonged pharmacological residual effect (4-6 weeks) that complicates cycle planning. No prospective study has evaluated linzagolix in this specific clinical scenario.

DESIGN:

Prospective before-after case series. Each patient serves as her own historical control (prior failed transfers under standard care vs outcome after linzagolix treatment). Treatment duration (3 or 6 months) is determined by morphological response at the month-3 ultrasound visit. Treatment extension to 6 months is indicated if any of the following criteria are met at month 3: uterine volume reduction \<20% from baseline, JZ maximum ≥12 mm, JZ difference ≥5 mm, or serum estradiol >40 pg/ml indicating incomplete hypothalamic-pituitary-ovarian axis suppression. Endometrial preparation is initiated 7 days after the last dose of linzagolix.

ULTRASOUND PROTOCOL:

Standardised transvaginal ultrasound measurements at each visit: uterine volume (L x AP x T x 0.523 cm3), junctional zone maximum (mm), junctional zone minimum (mm) and junctional zone difference (mm). All measurements performed in strict sagittal plane with ≥7 MHz transvaginal probe.

VASOMOTOR SYMPTOM MANAGEMENT:

Standardised non-estrogenic supplementation protocol (Cimicifuga racemosa 20 mg, Remifemin) if EVA score ≥4 for hot flushes or insomnia. Suspended simultaneously with the last dose of linzagolix.

REGULATORY FRAMEWORK:

Observational study with medicinal products (EOMF) under Spanish Royal Decree 957/2020. Use of linzagolix in this indication is off-label. Study approved by CEIm del Hospital Clinico San Carlos, Madrid (ref. 26/769-O_M_SP, October 13, 2026)."

02

Conditions studied

  • Adenomyosis of Uterus
  • Implantation Failure
  • Infertility Female
  • Embryo Transfer

Keywords

  • Linzagolix
  • Yselty
  • adenomyosis
  • recurrent implantation failure
  • junctional zone
  • live birth rate
  • oocyte donation
  • PGT-A
  • GnRH antagonist
  • endometrial receptivity
03

In context

Adenomyosis

142 studies on the registry are indexed under Adenomyosis; 54 are open to participants now.

This study's planned enrollment of 30 is below the median of 200 across 57 observational studies indexed under Adenomyosis.

Browse Adenomyosis studies →

Lead sponsor

This is the only study on the registry with Vida Fertility Institute as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women aged 18 to 50 years with confirmed adenomyosis (transvaginal ultrasound or MRI) and recurrent implantation failure, defined as 2 or more failed embryo transfers with high-quality blastocysts (grade BB or above in oocyte donation cycles, or PGT-A confirmed euploid blastocysts in autologous cycles), attending Vida Fertility Institute centres in Madrid, Alicante and San Sebastian, Spain.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 50 years
  • Confirmed adenomyosis by transvaginal ultrasound or MRI
  • Recurrent implantation failure defined as 2 or more failed embryo transfers with high-quality blastocysts: oocyte donation recipients (blastocyst grade BB or above, Gardner classification) OR autologous IVF cycles with PGT-A confirmed euploid blastocysts
  • Normal uterine cavity with no submucosal distortion
  • At least 1 suitable embryo available for transfer (blastocyst grade BB or above, or PGT-A euploid)
  • Signed written including explicit acknowledgement of off-label use of linzagolix

Exclusion criteria

Exclusion Criteria:

  • Untreated hydrosalpinx
  • Untreated stage III-IV endometriosis
  • Major uterine anomaly (uterine septum, bicornuate uterus)
  • Known to linzagolix including known hepatopathy
  • Prior treatment with linzagolix
  • GnRH analogue treatment within 6 months prior to enrolment
  • greater than 35 kg/m2
  • Prior failed transfers exclusively with embryos below the quality threshold (below BB grade, non-euploid)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • Linzagolix 200 mg - Adenomyosis and RIF

    Patients with confirmed adenomyosis and recurrent implantation failure (2 or more failed embryo transfers with high-quality blastocysts: grade BB or above in oocyte donation cycles, or PGT-A confirmed euploid in autologous cycles) receiving linzagolix 200 mg orally once daily for 3 to 6 months prior to embryo transfer. Treatment duration is determined at the month-3 visit based on morphological response (uterine volume reduction, junctional zone measurements) and serum estradiol levels (\>40 pg/ml indicating incomplete axis suppression). Endometrial preparation is initiated 7 days after the last dose of linzagolix.

    Drug: Linzagolix 200 mg (Yselty)

Interventions

  • DrugLinzagolixStudies of LinzagolixLinzagolix pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Linzagolix 200 mg orally once daily for a minimum of 3 months, extendable to 6 months based on morphological response (uterine volume and junctional zone assessment) and serum estradiol levels (\>40 pg/ml) at the month-3 visit.O ff-label use for adenomyosis prior to embryo transfer.

    Also known as: Yselty, GnRH receptor antagonist

06

What researchers measure

Primary outcomes

  1. Live Birth Rate (LBR) per embryo transfer

    Proportion of embryo transfers resulting in the birth of a live neonate at or beyond 24 weeks of gestation.

    Time frame: Up to 12 months after embryo transfer

Secondary outcomes

  1. Clinical Pregnancy Rate

    Proportion of embryo transfers resulting in the presence of an intrauterine gestational sac with fetal heartbeat on transvaginal ultrasound at 6-7 weeks of gestation.

    Time frame: 6-7 weeks after embryo transfer

  2. Miscarriage Rate

    Proportion of clinical pregnancies ending in spontaneous pregnancy loss before 22 weeks of gestation.

    Time frame: Up to 22 weeks of gestation

  3. Change in Uterine Volume

    Change in uterine volume (cm3) measured by transvaginal ultrasound using the ellipsoid formula (L x AP x T x 0.523) from baseline to post-treatment.

    Time frame: Baseline, month 3, month 6 (if applicable) and pre-transfer (approximately 3-7 months from baseline)

  4. Change in Junctional Zone Maximum Thickness

    Change in junctional zone (JZ) maximum thickness (mm) measured by standardised transvaginal ultrasound in strict sagittal plane from baseline to post-treatment.

    Time frame: Baseline, month 3, month 6 (if applicable) and pre-transfer (approximately 3-7 months from baseline)

  5. Incidence of Vasomotor Adverse Events

    Proportion of patients reporting hot flushes, insomnia or other vasomotor symptoms, assessed using a visual analogue scale (EVA 0-10) at each visit.

    Time frame: Monthly during treatment period (up to 6 months)

  6. Serum estradiol levels

    Serum estradiol levels (pg/ml) measured at baseline, month 1, month 3 and month 6 to assess degree of hypothalamic-pituitary-ovarian axis suppression during linzagolix treatment.

    Time frame: Baseline, month 1, month 3, month 6 (if applicable).

  7. Hepatic safety

    Hepatic function parameters (ALT, AST, GGT and total bilirubin) measured at baseline, month 3 and month 6 to assess liver safety during linzagolix treatment.

    Time frame: Baseline, month 3, month 6 (if applicable).

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: Undecided — Individual participant data will not be shared at this stage due to the small sample size and the need to protect patient privacy in accordance with the General Data Protection Regulation (GDPR, EU 2016/679) and Spanish Organic Law 3/2018 on Personal Data Protection. Anonymised aggregate data may be made available upon reasonable request following publication of the primary results.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jul 2028, 18 months later.

Of 31 observational studies under Adenomyosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 29. This study's planned 18 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Jan 2027, on Oct 21, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2026
First posted
Jul 13, 2026
StartEst.
Jan 1, 2027was Sep 2026
Primary completionEst.
Jul 1, 2028
CompletionEst.
Sep 1, 2028
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (2 Spain)
  • Vida Fertility Alicante · Alicante, Spain
  • Vida Fertility Institute Madrid · Madrid, Spain
Show 2 removed
  • Vida Fertility Alicante · Alicante, Spain
  • Vida Fertility Institute Madrid · Madrid, Spain
Oct 21, 2026
Start date
Sep 1, 2026→Jan 1, 2027
Oct 21, 2026
Enrollment
35→30
Oct 21, 2026
Secondary outcomes
2 added
What changed in the outcomes
  • AddedSerum estradiol levelsTime frame: Baseline, month 1, month 3, month 6 (if applicable).
  • AddedHepatic safetyTime frame: Baseline, month 3, month 6 (if applicable).
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    2 sites added, 2 sites removed
    Show 2 added (2 Spain)
    • Vida Fertility Alicante · Alicante, Spain
    • Vida Fertility Institute Madrid · Madrid, Spain
    Show 2 removed
    • Vida Fertility Alicante · Alicante, Spain
    • Vida Fertility Institute Madrid · Madrid, Spain
    Start date Sep 1, 2026→Jan 1, 2027
    Enrollment 35→30
    Secondary outcomes 2 added
    What changed in the outcomes
    • AddedSerum estradiol levelsTime frame: Baseline, month 1, month 3, month 6 (if applicable).
    • AddedHepatic safetyTime frame: Baseline, month 3, month 6 (if applicable).
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07698561
Lead sponsor
Vida Fertility Institute
Responsible party
Sponsor
First posted
Jul 13, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Jul 1, 2028 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Oct 21, 2026

Study contacts

Elena De Santiago Romero, MD
Contact
santiago.e@vidafertility.com
+34 679211353
Irene Hervas, PhD
Contact
hervas.i@vidafertility.com
+34 697766609

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion